Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

FEC + OV treatment of TNBC tumors

ABSTRACT: FEC + OV treatment of TNBC tumors

PROVIDER: PRJNA640141 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12038015.fastq.gz	Fastqsanger.gz
	SRR12038016.fastq.gz	Fastqsanger.gz
	SRR12038017.fastq.gz	Fastqsanger.gz
	SRR12038018.fastq.gz	Fastqsanger.gz
	SRR12038019.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 60

Similar Datasets

FEC + OV treatment of TNBC tumors

Project description:E0771 subcutaneous tumors in C57/Bl6 mice were treated with saline, FEC (chemotherapy), oHSV-1 (oncolytic virus) or FEC + oHSV-1

2021-06-21 | GSE152698 | GEO

Transcriptomic analysis of E0771 tumors treated with FEC + oHSV-1 Vs PBS

Project description:E0771 tumors were implanted either subcutaneously on the left flank or orthotopically in the mammary fat pad and treated with either PBS or FEC + oHSV-1 Mice were sacrificed 5 days after the start of treatment and whole tumour digests were used for RNA extraction

2021-10-01 | GSE183864 | GEO

DNA methylation profiling of TNBC primary tumors

Project description:DNA methylation profiling of TNBC primary tumors (surgically resected) to validate DNA methylation epitypes. Illumina EPIC V1 set DNA methylation profiling of TNBC primary tumors (surgically resected) to validate DNA methylation epitypes. Illumina EPIC V2 set (GSM8826913-GSM8826971).

2025-03-03 | GSE290981 | GEO

DNA methylation profiling of TNBC primary tumors

Project description:DNA methylation profiling of TNBC primary tumors

| PRJNA1231115 | ENA

NGS PHRC OV

Project description:NGS PHRC OV

| PRJNA1130994 | ENA

Transcriptomic analysis of E0771 tumors treated with FEC + oHSV-1 Vs PBS

Project description:Transcriptomic analysis of E0771 tumors treated with FEC + oHSV-1 Vs PBS

| PRJNA762241 | ENA

Effect of Sulfopin and Abemaciclib treatment on gene expression in mouse TNBC

Project description:To investigate the role of combined PIN1 and CDK4 inhibition in the regulation of immune response, we performed RNA sequencing of TNBC tumors after treatment with Sulfopin, Abemaciclib or their combination

2024-03-08 | GSE232422 | GEO

Comprehensive genomic analysis identify novel subtypes and targets of triple-negative breast cancer (198 TNBC tumors)

Project description:Recent meta-analyses suggest triple-negative breast cancer (TNBC) is a heterogenous disease. In this study we sought to define these TNBC subtypes and identify subtype-specific markers and targets. We identified and confirmed four distinct, stable TNBC subtypes: (1) Luminal-AR (LAR); 2) Mesenchymal (MES); 3) Basal-Like Immune-Suppressed (BLIS), and 4) Basal-Like Immune-Activated (BLIA). RNA profiling analysis was conducted on 198 TNBC tumors (ER-negativity defined as Allred Scale value â¤2) with >50% cellularity (discovery set: n=84; validation set: n=114)

2015-12-18 | E-GEOD-76124 | biostudies-arrayexpress

Transcriptome profiling of tumors from Kenyan triple negative breast cancer (TNBC) patients.

Project description:Triple negative breast cancer is an aggressive phenotypic breast cancer characterized by ER negative, PR negative and Her2 negative immunohistochemistry status. We embarked on a study to explore the transcriptome of Kenyan TNBC patients and identify potential biomarkers specific to Kenyan population. The transcriptome sequencing of tumors from Kenyan TNBC patients and comparisons with African American and Caucasian TNBC transcriptomes revealed several interesting targets and dysregulated pathways.

2021-04-28 | GSE142258 | GEO

14d OV scRNA-seq

Project description:14d OV scRNA-seq

| PRJNA597329 | ENA